Halo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland)The ...

China's CSPC Pharmaceutical signs deal with AstraZeneca for weight loss therapy

By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, ...

AI and pharmaceutical medicine development: A new standard is in the making

AI: How does this technological revolution fit with the pharmaceutical regulators who oversee the pharmaceutical sector at ...

Thermo Fisher beats quarterly results estimates on demand for tools from pharma clients

Jan 29 (Reuters) - Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on ...
PharmTech

Halo Pharma Becomes Dedicated North American Drug Product CDMO

Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026 ...
Drug Target Review

Drug development in 2026: NAMs, safety and regulatory changes

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its ...
PharmExec

Insilico Medicine Enters $120 Million Drug Development Collaboration with Qilu Pharmaceuticals to Advance Cardiometabolic Therapies

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...

Mark Cuban Cost Plus Drugs and Alchem Laboratories Announce Alliance to Advance Essential Medicines

DALLAS, TX, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) ...
Morningstar

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

Boehringer Ingelheim in deal with China's Simcere Pharma to license IBD drug candidate

SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...